Clearside BioMedical, Inc Stock News

New Jersey, United States,- Verified Market Research has recently published a research report titled, Diabetic Macular Edema Market Size, and Forecast 2021-2028, Breakdown Data by Manufacturers, Key Regions, Types and Application. Primary and secondary research methodologies have been used to

ALPHARETTA, Ga., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that the Company will be added to the Nasdaq Biotechnology Index (Nasdaq: NBI), effective prior to market open on Monday, December 20, 2021.

Equities analysts forecast that Clearside Biomedical, Inc. (NASDAQ:CLSD) will announce earnings of $0.10 per share for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for Clearside Biomedicals earnings, with estimates ranging from ($0.08) to $0.27. Clearside Biomedical reported earnings of ($0.14) per share in the same quarter last year, which []

State Street Corp raised its position in Clearside Biomedical, Inc. (NASDAQ:CLSD) by 316.7% during the second quarter, HoldingsChannel reports. The firm owned 165,588 shares of the companys stock after buying an additional 125,848 shares during the quarter. State Street Corps holdings in Clearside Biomedical were worth $806,000 as of its most recent SEC filing. Several []

Clearside Biomedical, Inc. (NASDAQ:CLSD) was the target of a significant drop in short interest during the month of November. As of November 15th, there was short interest totalling 1,050,000 shares, a drop of 52.3% from the October 31st total of 2,200,000 shares. Based on an average trading volume of 512,500 shares, the short-interest ratio is []

Clearside Biomedical, Inc. (NASDAQ:CLSD) was the target of a significant decline in short interest in the month of November. As of November 15th, there was short interest totalling 1,050,000 shares, a decline of 52.3% from the October 31st total of 2,200,000 shares. Approximately 2.2% of the companys shares are sold short. Based on an average []

Equities research analysts predict that Clearside Biomedical, Inc. (NASDAQ:CLSD) will report sales of $13.73 million for the current quarter, according to Zacks Investment Research. Four analysts have provided estimates for Clearside Biomedicals earnings. The lowest sales estimate is $3.07 million and the highest is $24.00 million. Clearside Biomedical posted sales of $10,000.00 during the same []

Clearside Biomedical, Inc. (NASDAQ:CLSD) saw a large growth in short interest in the month of October. As of October 29th, there was short interest totalling 2,200,000 shares, a growth of 81.8% from the October 14th total of 1,210,000 shares. Based on an average trading volume of 553,200 shares, the days-to-cover ratio is currently 4.0 days. […]

Walleye Capital LLC bought a new position in shares of Clearside Biomedical, Inc. (NASDAQ:CLSD) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 18,000 shares of the companys stock, valued at approximately $88,000. Other hedge funds have also recently added to or []

Clearside Biomedical (NASDAQ:CLSD) was upgraded by Zacks Investment Research from a sell rating to a hold rating in a report issued on Monday, Zacks.com reports. According to Zacks, Clearside Biomedical, Inc. is a biopharmaceutical company is engaged in developing first-in-class drug therapies to treat blinding diseases of the eye using Clearside proprietary suprachoroidal space(TM) microinjector. []

Investigational therapeutics injected via the SCS Microinjector® demonstrate positive clinical data in wet AMD, diabetic retinopathy, and choroidal melanoma in partner programs Investigational therapeutics injected via the SCS Microinjector® demonstrate positive clinical data in wet AMD, diabetic retinopathy, and choroidal melanoma in partner programs

Clearside Biomedical, Inc. (NASDAQ:CLSD) Analysts at Wedbush upped their FY2021 earnings per share (EPS) estimates for shares of Clearside Biomedical in a note issued to investors on Thursday, November 11th. Wedbush analyst L. Moussatos now anticipates that the company will earn ($0.39) per share for the year, up from their previous estimate of ($0.42). []

Clearside Biomedical, Inc. (CLSD) CEO George Lasezkay on Q3 2021 Results - Earnings Call Transcript

Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of 11.11% and -7.30%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for th